HistoSonics has completed a $102 million Series D financing round, the funds of which will go toward developing the company's histotripsy offerings.
The round was led by Alpha Wave Ventures, with participation from new investors Amzak Health and HealthQuest Capital, as well as existing investors Johnson & Johnson Innovation - JJDC, Venture Investors, Lumira Ventures, Yonjin Venture, and the State of Wisconsin Investment Board.
HistoSonics Edison Histotripsy System.Business Wire
The funding will be used to further develop the company's noninvasive histotripsy platforms, support commercial growth in the U.S. and other global markets, and begin HistoSonics' BOOMBOX Master Study that will evaluate its Edison Histotripsy System for treating liver tumors.
Edison received de novo clearance in October 2023 from the U.S. Food and Drug Administration (FDA). HistoSonics is also partnering with institutions across the U.S. and around the world in developing multidisciplinary histotripsy liver programs.
